Clinical trial
Continuous Outcome Modeling by Pressure Variability and Small Vessel Status in Acute Ischemic Stroke: A Prospective Observational Cohort Study (COMPASS)
NCT07903922 is registered in ClinicalTrials.gov with Minyoul Baik as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Recruiting, started November 2026. Observational study, 450 participants (estimated). Lead sponsor Minyoul Baik; South Korea. Primary measure: Poor functional outcome (modified Rankin Scale 3-6) at discharge.
How it compares
54 similar trials: same condition (Cerebral Small Vessel Diseases) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- Continuous Outcome Modeling by Pressure Variability and Small Vessel Status in Acute Ischemic Stroke: A Prospective Observational Cohort Study (COMPASS)
- Lead sponsor
- Minyoul Baik
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- November 6, 2026
- Completion date
- September 30, 2029
- Enrollment
- 450 (estimated)
- Sites
- 1
Conditions
MeSH condition names; the registry's own terms follow.
Cerebral Small Vessel Diseases, Ischemic Stroke
Registry terms: blood pressure variability, cerebral small vessel disease, ischemic stroke, acute, white matter hyperintensity
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 19 Years
- Healthy volunteers
- No
- Study type
- Observational
- Sites
- 1
- Countries
- South Korea
- Lead sponsor
- Minyoul Baik
Arms
As registered; 1 arm.
| Arm | Type | Interventions |
|---|---|---|
| Acute ischemic stroke with 72-hour continuous BP monitoring | Cuffless ring-type continuous blood pressure monitor | |
Show registry wordingAdults with acute ischemic stroke presenting within 24 hours of onset who undergo up to 72 hours of cuffless continuous blood pressure monitoring with a ring-type wearable device. Analyzed as a single cohort with blood pressure variability as a continuous exposure; a prespecified subgroup is defined by white matter hyperintensity severity (Fazekas total \>=3 vs \<3). | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Poor functional outcome (modified Rankin Scale 3-6) at discharge | At discharge or transfer from the neurology service, whichever occurs first (an average of 7 days) |
Show registry wordingFunctional outcome measured by the modified Rankin Scale (mRS), a 7-level scale from 0 (no symptoms) to 6 (death). Poor outcome is defined as mRS 3-6 versus good outcome mRS 0-2, assessed at hospital discharge. The primary analysis relates this outcome to systolic blood pressure variability (standard deviation) over the first 72 hours. | |
Similar trials
Same condition (Cerebral Small Vessel Diseases) and phase, most recent start first.
+49 more trials See the condition page